General information with sources. Never a substitute for your doctor.

MethodologyAbout the authorESEN
SaciedadSearch

GLP-1News

CagriSema: What It Is, What the REDEFINE Trials Showed and When It Could Be Approved

CagriSema, Novo Nordisk's cagrilintide and semaglutide combination, is not approved anywhere. REDEFINE trial results, comparisons and FDA filing status.

Written by
Published
Next review
Sources
29 primary and 7 supporting

No clinical review. No advertising from drug companies and no affiliate links.How we work

As of October 5, 2026, CagriSema is an investigational combination from Novo Nordisk: a once-weekly injection that pairs cagrilintide 2.4 mg, which mimics the hormone amylin, with semaglutide 2.4 mg69. Semaglutide is the active ingredient in Ozempic and Wegovy. CagriSema is not approved in any country. Novo Nordisk submitted it to the FDA in December 2025 and expects a decision in the fourth quarter of 202668. It does not appear among the FDA’s novel drug approvals for 2026[27]. In its main trial, REDEFINE 1, with 3,417 adults without diabetes, body weight fell by an average of 20.4% over 68 weeks, versus 3.0% on placebo, counting every participant whether or not they stayed on treatment[1].

This is general information, not treatment guidance. If you are considering this or any other medication, talk to your doctor.

In 30 seconds

  • Not approved anywhere. According to Novo Nordisk, the US application is in and the FDA’s decision is expected in the fourth quarter of 2026827.
  • REDEFINE 1, published in NEJM: −20.4% body weight at 68 weeks, versus −3.0% on placebo[1].
  • REDEFINE 2, in type 2 diabetes, also in NEJM: −13.7%, versus −3.4%[2].
  • In the only head-to-head obesity trial against tirzepatide, REDEFINE 4, CagriSema did not show non-inferiority: −20.2% versus −23.6%, according to Novo Nordisk; there is no paper yet[7].
  • The large cardiovascular outcomes trial, REDEFINE 3, with 7,101 participants, has an estimated primary completion date of September 2027[17].

What CagriSema is

CagriSema is not a new molecule but two, given together once a week as an injection under the skin19:

  • Cagrilintide, a long-acting amylin analog developed by Novo Nordisk[13]. In the phase 1b trial its half-life was 159 to 195 hours, long enough for once-weekly dosing[13].
  • Semaglutide, a GLP-1 receptor agonist. The 2.4 mg dose is the same one tested in STEP 1, semaglutide’s large obesity trial[31]. Everything about it is in the semaglutide guide.

Amylin is another hormone. According to the FDA label for pramlintide, an amylin analog approved for diabetes, amylin is released by the pancreas together with insulin in response to food, slows stomach emptying, suppresses glucagon secretion and regulates food intake through the brain[14]. GLP-1 also curbs appetite, but through different receptors. The idea behind the combination is to add the two pathways together, which is why it was tested against each component on its own[1].

Novo Nordisk is studying it in two programs: REDEFINE, for obesity and overweight, and REIMAGINE, for type 2 diabetes[9]. It has no label, so there is no approved dosing schedule. Where it fits in the drug family is explained in what GLP-1 medications are, and the brand names are in GLP-1 generic and brand names.

REDEFINE 1 and REDEFINE 2: the two pivotal trials

These are the two phase 3 trials behind the FDA submission[7]. Both ran for 68 weeks, were funded by Novo Nordisk and included a lifestyle intervention in every group12.

Trial Participants Groups Weight on CagriSema Placebo Source
REDEFINE 1 (summary) 3,417 adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition, no diabetes CagriSema (2,108), semaglutide alone (302), cagrilintide alone (302), placebo (705) −20.4% −3.0% NEJM 2025115
REDEFINE 2 (summary) 1,206 adults with type 2 diabetes, a BMI of 27 or more and an HbA1c of 7% to 10% CagriSema (904), placebo (302) −13.7% −3.4% NEJM 2025216

BMI: body mass index, in kg/m². HbA1c: glycated hemoglobin, a measure of average blood sugar over the past few months. Both trials had US sites1516.

  • REDEFINE 1. The difference from placebo was 17.3 percentage points (95% confidence interval, 16.6 to 18.1)[1]. According to Novo Nordisk, with the same analysis, semaglutide alone lowered weight by 14.9% and cagrilintide alone by 11.5%[3]. Those two figures are not in the paper’s abstract. If everyone had stayed on treatment, weight loss would have been 22.7%, versus 2.3% on placebo, and 40.4% would have lost at least 25% of their weight, versus 16.2% on semaglutide alone[3].
  • REDEFINE 2. The difference from placebo was 10.4 points (9.5 to 11.2). An HbA1c of 6.5% or less was reached by 73.5% on CagriSema, versus 15.9% on placebo[2]. If everyone had stayed on treatment, according to Novo Nordisk, weight loss would have been 15.7%, versus 3.1%[4]. As with the other drugs in the family, people with type 2 diabetes lose less weight.

Three details for reading the numbers

Which analysis. The papers lead with the treatment-policy estimand: it counts everyone who started, whether or not they stayed on the drug12. The press releases tend to highlight another analysis, which assumes everyone stayed on treatment and gives larger numbers34. I use the papers’ figures and add the other one where it exists.

Dosing was flexible. Both trials let participants adjust their dose during the study. At 68 weeks, only 57.3% of people on CagriSema in REDEFINE 1, and 61.9% in REDEFINE 2, were on the highest dose34. So the −20.4% is not the effect of 2.4 mg + 2.4 mg in every participant, but of a strategy in which roughly four in ten were not on the top dose at the end.

Stopping treatment. According to Novo Nordisk, 6% on CagriSema and 3.7% on placebo stopped because of side effects in REDEFINE 1, and 8.4% versus 3% in REDEFINE 2[5]. Those figures are not in the papers’ abstracts. In REDEFINE 5, in Japan and Taiwan, 10% stopped CagriSema and 6% stopped semaglutide alone, for any reason[10].

The rest of the REDEFINE program

I checked the status of each trial on ClinicalTrials.gov on October 5, 2026. Only some records carry the REDEFINE number; for the others, the match comes from how Novo Nordisk describes them.

Trial What it compares Participants Length Status
REDEFINE 3 CagriSema vs. placebo on cardiovascular events 7,101 adults aged 55 or older with established cardiovascular disease Up to 242 weeks or more Active, not recruiting; estimated primary completion September 2027[17]
REDEFINE 4 CagriSema vs. tirzepatide 15 mg, open-label 809 adults with obesity, US only 84 weeks Completed January 2026; results by press release718
REDEFINE 5 (summary) CagriSema vs. semaglutide 2.4 mg 331 adults in Japan and Taiwan, with or without diabetes 68 weeks Completed; paper in Lancet Diabetes & Endocrinology (2026)1019
REDEFINE 6 CagriSema vs. semaglutide and placebo 300 adults in China 44 weeks Completed February 2025; I have not found a paper[20]
REDEFINE 9 Lower doses (1.0 + 1.0 and 1.7 + 1.7 mg) vs. placebo 300 adults in the US, Canada and Europe 68 weeks Completed April 2026; results by press release821
REDEFINE 11 CagriSema vs. placebo, with a weight-maintenance extension 609 adults with obesity, US only 80 weeks Active; data expected in the first half of 2027722
NCT06780449 CagriSema vs. placebo, long term About 400 adults with obesity, including US sites 104 weeks Active; estimated primary completion August 2028[23]
NCT07564414 Two CagriSema dose levels vs. semaglutide About 2,500 adults with obesity, with or without diabetes, including US sites 72 weeks Recruiting since May 2026; estimated primary completion February 2028[24]
  • REDEFINE 4. The only direct comparison with tirzepatide in obesity. According to Novo Nordisk, with the treatment-regimen estimand weight fell by 20.2% on CagriSema and 23.6% on tirzepatide at 84 weeks; with the efficacy estimand, by 23.0% and 25.5%. The trial did not meet its primary endpoint, which was to show that CagriSema is non-inferior to tirzepatide[7]. It was open-label: participants and investigators knew which drug each person received718.
  • REDEFINE 5. Weight fell by 18.4% on CagriSema and 11.9% on semaglutide alone, a difference of 6.5 points (4.6 to 8.4)[10]. Note that this paper’s main analysis assumes everyone took the treatment as intended, so it is not comparable with REDEFINE 1’s −20.4%[10].
  • REDEFINE 9. According to Novo Nordisk, weight fell by 21.0% on 1.0 + 1.0 mg, versus 2.0% on placebo, using the efficacy estimand[8]. The release gives neither the 1.7 + 1.7 mg figure nor the figure that counts every participant. Until it is published, treat it with caution.
  • Higher dose. According to Novo Nordisk, a phase 3 trial of cagrilintide 2.4 mg with semaglutide 7.2 mg in adults with obesity started in 2026[9]. I could not confirm which ClinicalTrials.gov record matches it.

REIMAGINE, in type 2 diabetes. In REIMAGINE 2, published in 2026, with 2,713 adults, HbA1c fell by 1.91 points on CagriSema and 1.75 on semaglutide 2.4 mg alone at 68 weeks; the 0.16-point difference was statistically significant[11]. REIMAGINE 5 compared it with low-dose tirzepatide; I summarize it below[8].

Is CagriSema FDA approved? Regulatory status

Region Status as of October 5, 2026 Source
United States Not approved. Application submitted to the FDA in December 2025 for weight management in adults with obesity, or overweight with at least one weight-related condition. Novo Nordisk expects a decision in the fourth quarter of 2026. Not among the FDA’s novel drug approvals for 2026 (list current as of September 28) and not in Drugs@FDA Novo Nordisk68; FDA2728
European Union Not approved. Not on the EMA’s list of applications under review (data as of September 4) EMA[26]

The FDA does not publish the applications it is reviewing: the submission and the expected timing come from Novo Nordisk, not from the agency. An expected decision is not an approval; the FDA can approve, ask for more data or decline.

When could it be approved?

There is no confirmed date. The only timeline is Novo Nordisk’s: it expects the FDA’s decision in the fourth quarter of 2026[8]. The submission covers weight management only; type 2 diabetes is being studied separately in the REIMAGINE trials69. Even after an approval, reaching pharmacies is a separate step. In Europe, there was no application on the EMA’s list as of September 4, 2026[26].

CagriSema vs. semaglutide, tirzepatide, retatrutide and survodutide

All of these are once-weekly injections that act on the GLP-1 receptor. What differs is what they add:

Drug What it activates Status as of October 5, 2026
Semaglutide (Ozempic, Wegovy) GLP-1[31] Approved
Tirzepatide (Mounjaro, Zepbound) GIP and GLP-1[32] Approved
CagriSema Amylin (cagrilintide) and GLP-1 (semaglutide), two molecules[1] Not approved; FDA application submitted, according to Novo Nordisk[6]
Retatrutide GIP, GLP-1 and glucagon, one molecule[33] Investigational
Survodutide Glucagon and GLP-1, one molecule[34] Investigational

The direct comparisons that exist:

  • Against semaglutide alone: REDEFINE 1, REDEFINE 5 and REIMAGINE 2, all double-blind11011. Average weight loss was larger with the combination than with semaglutide alone in REDEFINE 1, according to Novo Nordisk, and in REDEFINE 5, according to the paper310. In the 32-week phase 2 diabetes trial, with 92 people in the US, HbA1c did not fall significantly more than with semaglutide alone[12].
  • Against tirzepatide: REDEFINE 4 in obesity, with CagriSema 2.4 + 2.4 mg and tirzepatide 15 mg, did not show that CagriSema is non-inferior[7]. REIMAGINE 5, in 1,023 adults with type 2 diabetes and with low doses of both (CagriSema 1.0 + 1.0 mg and tirzepatide 5 mg), showed, according to Novo Nordisk and using the efficacy estimand, 12.4% weight loss on CagriSema and 9.1% on tirzepatide at 60 weeks, with an HbA1c reduction that was non-inferior (1.71 versus 1.67 points)825. Both were open-label, and neither has a published paper yet1825.
  • Against retatrutide or survodutide: I have not found any trial on ClinicalTrials.gov.

Beyond that, trials can only be set side by side, using the analysis that counts every participant:

Drug and trial Participants Length Weight on the highest dose Placebo
CagriSema 2.4 + 2.4 mg, REDEFINE 1 3,417 without diabetes 68 weeks −20.4%[1] −3.0%
Semaglutide 2.4 mg, STEP 1 1,961 without diabetes 68 weeks −14.9%[31] −2.4%
Tirzepatide 15 mg, SURMOUNT-1 2,539 without diabetes 72 weeks −20.9%[32] −3.1%
Retatrutide 12 mg, TRIUMPH-1 2,339 without diabetes 80 weeks −25.0%[33] −3.9%
Survodutide 6.0 mg, SYNCHRONIZE-1 725 without diabetes 76 weeks −13.0%[34] −5.4%
CagriSema 2.4 + 2.4 mg, REDEFINE 2 1,206 with type 2 diabetes 68 weeks −13.7%[2] −3.4%
Semaglutide 2.4 mg, STEP 2 1,210 with type 2 diabetes 68 weeks −9.6%[35] −3.4%
Tirzepatide 15 mg, SURMOUNT-2 938 with type 2 diabetes 72 weeks −14.7%[36] −3.2%

The rows can’t be subtracted from each other. The trials ran for different lengths, in different years and countries, and handled dosing differently: REDEFINE 1 and 2 allowed dose adjustments, and about four in ten did not end on the top dose34. Semaglutide and tirzepatide are approved, with FDA labels and years of use; the other three are not. The retatrutide and survodutide guides cover each in detail, as do the guides to amycretin and maridebart cafraglutide (MariTide). More trial figures are charted in the trial results chart.

Side effects in the trials

Without a label, there is no official list of side effects, contraindications or warnings. This is what the papers and press releases report:

  • Digestive. The most common, generally mild to moderate and short-lived. In REDEFINE 1 they affected 79.6% on CagriSema and 39.9% on placebo[1]. According to Novo Nordisk, nausea affected 55% (12.6% on placebo), constipation 30.7% (11.6%) and vomiting 26.1% (4.1%)[5]. In REDEFINE 2, 72.5% versus 34.4%[2].
  • Compared with semaglutide alone. In REDEFINE 5, digestive side effects affected 53% on CagriSema and 51% on semaglutide[10]. In REIMAGINE 2, side effects of any kind affected 86.9% and 81.2%[11].

For digestive symptoms on approved GLP-1 drugs: what to eat with nausea and constipation on GLP-1s.

Compounded or “research” cagrilintide

Can you buy it? Not legally. The FDA states that cagrilintide cannot be used in compounding under federal law, that it is not a component of any FDA-approved drug and that it has not been found safe and effective for any condition[29]. On March 31, 2026, the FDA sent a warning letter to a company selling, among other things, a product called “Cagrilintide” online. Although it was labeled “for laboratory research purposes only,” the FDA concluded it was an unapproved new drug intended for use in people[30]. The FDA urges consumers not to buy products falsely labeled “for research purposes” or “not for human consumption,” because their quality is unknown[29].

The REDEFINE results come from a product made by Novo Nordisk and say nothing about a vial bought online. If you have already used one, tell your doctor. For other products sold as alternatives, see natural Ozempic and supplements.

What is still unknown

  • Cardiovascular safety and benefit. REDEFINE 3 measures whether CagriSema changes the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke, with an estimated primary completion date of September 2027[17].
  • What happens after stopping. The REDEFINE 1 extension follows people who received CagriSema or placebo for 97 weeks off treatment, with an estimated end date of October 19, 2026[15]. What is known for other GLP-1 drugs is in stopping GLP-1s and weight regain.
  • Beyond 68 weeks. The 80-week and 104-week trials will not report until 2027 and 2028723.
  • How it compares with tirzepatide. The REDEFINE 4 and REIMAGINE 5 results are known only from press releases, without the detail of a peer-reviewed paper78.

Frequently asked questions

What is CagriSema and what is it for?

It is an investigational once-weekly combination of cagrilintide, an amylin analog, and semaglutide, from Novo Nordisk[9]. It is being studied for obesity and overweight (the REDEFINE program) and for type 2 diabetes (the REIMAGINE program)[9]. It is not approved for either.

When will CagriSema be FDA approved?

There is no confirmed date. Novo Nordisk expects the FDA’s decision in the fourth quarter of 2026, but an expected decision does not guarantee approval[8]. As of September 28, 2026, it was not on the FDA’s list of novel drug approvals for the year[27].

Is CagriSema better than Wegovy or Zepbound?

The data do not support a simple answer. Against semaglutide alone, average weight loss was larger in REDEFINE 1 and REDEFINE 5310. Against tirzepatide 15 mg, in REDEFINE 4, non-inferiority was not shown[7]. Wegovy and Zepbound are FDA approved and CagriSema is not. What fits a given person is a decision for their prescriber.

Can you buy cagrilintide or CagriSema online?

Not legally. Neither is FDA approved, cagrilintide cannot be compounded under federal law, and the FDA has sent a warning letter to a seller of “Cagrilintide” labeled for research use272930. Outside its clinical trials, I have not found any legal way to get it.

Sources

Sources consulted for this article, with the access date.

  1. Clinical trialNew England Journal of Medicine.Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647.accessed .
  2. Clinical trialNew England Journal of Medicine.Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648-659.accessed .
  3. PressNovo Nordisk A/S (GlobeNewswire).Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial (December 20, 2024).accessed .
  4. PressNovo Nordisk A/S (GlobeNewswire).Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial (March 10, 2025).accessed .
  5. PressNovo Nordisk Inc. (PR Newswire).CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM (June 22, 2025).accessed .
  6. PressNovo Nordisk A/S.Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management (December 18, 2025).accessed .
  7. PressNovo Nordisk A/S (GlobeNewswire).Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved (February 23, 2026).accessed .
  8. PressNovo Nordisk A/S (GlobeNewswire).Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial (includes REDEFINE 9) (September 21, 2026).accessed .
  9. PressNovo Nordisk A/S (GlobeNewswire).Novo's investigational obesity and diabetes drug CagriSema reduces food noise and shows benefits in organ and bone health, EASD 2026 (September 30, 2026).accessed .
  10. Clinical trialThe Lancet Diabetes & Endocrinology.Yamauchi T, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5). Lancet Diabetes Endocrinol. 2026;14(6):450-462.accessed .
  11. Clinical trialThe Lancet Diabetes & Endocrinology.Buse JB, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes Endocrinol. 2026;14(8):662-677.accessed .
  12. Clinical trialThe Lancet.Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a phase 2 trial. Lancet. 2023;402(10403):720-730.accessed .
  13. Clinical trialThe Lancet.Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a phase 1b trial. Lancet. 2021;397(10286):1736-1748.accessed .
  14. Drug labelDailyMed (US National Library of Medicine).Symlin (pramlintide) injection: US Prescribing Information (section 12.1, mechanism of action).accessed .
  15. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1), NCT05567796.accessed .
  16. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2), NCT05394519.accessed .
  17. Official databaseClinicalTrials.gov (US National Library of Medicine).REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels, NCT05669755.accessed .
  18. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (REDEFINE 4), NCT06131437.accessed .
  19. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight (REDEFINE 5), NCT05813925.accessed .
  20. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (REDEFINE 6), NCT05996848.accessed .
  21. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight, NCT06388187.accessed .
  22. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term, NCT07011667.accessed .
  23. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity, NCT06780449.accessed .
  24. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight, NCT07564414.accessed .
  25. Official databaseClinicalTrials.gov (US National Library of Medicine).A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (REIMAGINE 5), NCT06534411.accessed .
  26. RegulatorEuropean Medicines Agency (EMA).Applications for new human medicines under evaluation by the CHMP, September 2026 (data extracted September 4, 2026; cagrilintide not listed).accessed .
  27. RegulatorU.S. Food and Drug Administration (FDA).Novel Drug Approvals for 2026 (content current as of September 28, 2026; CagriSema not listed).accessed .
  28. Official databaseU.S. Food and Drug Administration (Drugs@FDA).Drugs@FDA: search for the active ingredient “cagrilintide,” no results as of the access date.accessed .
  29. RegulatorU.S. Food and Drug Administration (FDA).FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026).accessed .
  30. RegulatorU.S. Food and Drug Administration (FDA).Warning letter to Prime Sciences, 721805 (includes a product called “Cagrilintide”) (March 31, 2026).accessed .
  31. Clinical trialNew England Journal of Medicine.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.accessed .
  32. Clinical trialNew England Journal of Medicine.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.accessed .
  33. Clinical trialNew England Journal of Medicine.Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published online September 29, 2026.accessed .
  34. Clinical trialNew England Journal of Medicine.le Roux CW, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1). N Engl J Med. 2026;395(8):776-787.accessed .
  35. Clinical trialThe Lancet.Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.accessed .
  36. Clinical trialThe Lancet.Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.accessed .

Related guides

Useful tools: Monthly cost of a GLP-1Questions to ask your doctor about GLP-1